Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
Odronextamab achieved high complete response rates with generally manageable safety in patients with heavily pretreated R/R follicular lymphoma.
Authors
- Yue Song (ORCID: https://orcid.org/0000-0003-0898-5281)
- Jurriaan Brouwer‐Visser (ORCID: https://orcid.org/0009-0007-3839-6791)
- W. Zhang
- Deepa Jagadeesh (ORCID: https://orcid.org/0000-0002-1772-0659)
- Stefano Luminari (ORCID: https://orcid.org/0000-0001-8446-2285)
- Srikanth Ambati
- Ana Jiménez Ubieto (ORCID: https://orcid.org/0000-0003-0892-8682)
- Aránzazu Alonso
- Hesham Mohamed (ORCID: https://orcid.org/0000-0002-9044-366X)
- Shuhua Yi (ORCID: https://orcid.org/0000-0002-6291-812X)
- Michał Taszner (ORCID: https://orcid.org/0000-0002-8437-2797)
- Salimah Z. Shariff (ORCID: https://orcid.org/0000-0002-1219-6763)
- José C. Villasboas (ORCID: https://orcid.org/0000-0002-2907-0809)
- M. Tani
- David Tucker (ORCID: https://orcid.org/0000-0002-0481-4111)
- Stéphanie Guidez (ORCID: https://orcid.org/0000-0001-8755-5591)
- Biyi Shen (ORCID: https://orcid.org/0000-0002-0936-4260)
- Emmanuel Bachy (ORCID: https://orcid.org/0000-0003-2694-7510)
- Jan Walewski (ORCID: https://orcid.org/0000-0003-4247-2674)
- Seok‐Goo Cho (ORCID: https://orcid.org/0000-0002-5429-4839)
- Michele Merli (ORCID: https://orcid.org/0000-0002-0905-5927)
- Silvana Novelli (ORCID: https://orcid.org/0000-0001-8750-0195)
- Laura Magnano (ORCID: https://orcid.org/0000-0002-6928-8386)
- Benoît Tessoulin (ORCID: https://orcid.org/0000-0001-7600-3329)
- Elżbieta Iskierka‐Jazdzewska (ORCID: https://orcid.org/0000-0003-2772-8870)
- Geoffrey Chong (ORCID: https://orcid.org/0000-0003-4006-2380)
- Amulya Uppala (ORCID: https://orcid.org/0000-0001-5457-9298)
- Li Mei Poon
- Min Zhu (ORCID: https://orcid.org/0000-0002-5669-9602)
- Tae Min Kim (ORCID: https://orcid.org/0000-0001-6145-4426)
- Arvind Chaudhry
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Goddard Space Flight Center (US)
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Inserm (FR)
- Tianjin University (CN)
- Regeneron (United States) (US)
- Chinese Academy of Sciences (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Nankai University (CN)
- Royal Cornwall Hospital (GB)
- Peking Union Medical College Hospital (CN)
- Hospital de Sant Pau (ES)
- Seoul National University Hospital (KR)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Centre Hospitalier Universitaire de Nantes (FR)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- ASL Roma (IT)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Ospedale "Santa Maria delle Croci" di Ravenna (IT)
- Peking University Cancer Hospital (CN)
- Regenerys (United Kingdom) (GB)
- Groupe de Recherche en Droit, Économie, Gestion (FR)
- Hospices Civils de Lyon (FR)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Quirónsalud Madrid (ES)
- Copernicus Memorial Hospital (PL)
- Centre Hospitalier Universitaire de Poitiers (FR)
- National Center for Tumor Diseases (DE)
- Institute of Plasma Physics (CN)
- Uczelnia Warszawska im. Marii Skłodowskiej-Curie (PL)
- Medical University of Lodz (PL)
- National University Hospital (SG)
- Mayo Clinic in Florida (US)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Olivia Newton-John Cancer Wellness & Research Centre (AU)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Centre International de Recherche en Infectiologie (FR)
- Laboratoire de recherche en gestion et économie
- Gdańsk Medical University (PL)
- Catholic University of Korea (KR)
- Nantes Université (FR)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1016/j.annonc.2024.08.2239
- Citations
- 69
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 29.32
Funders
- Amgen
- Pfizer
- AstraZeneca
- Gilead Sciences
- Regeneron Pharmaceuticals
- Atara Biotherapeutics
- MEI Pharma
- Incyte
- Seagen
- Genentech
- Pharmacyclics
- Loxo Oncology